Northwest Biotherapeutics (NWBO): Initiating with an Outperform Rating - Analyst Blog
December 13 2011 - 5:18AM
Zacks
Northwest Biotherapeutics (NWBO): Initiating with an
Outperform Rating
Grant Zeng, CFA
Northwest Biotherapeutics, Inc.
(NWBO) is a clinical stage biotechnology
company focused on discovery, development and commercialization of
immunotherapy products to safely generate and
enhance immune system responses to effectively treat cancers. The
Company holds two technology platforms applicable to cancer
therapeutics: dendritic cell (DC)-based cancer
vaccines (DCVaxTM), and monoclonal
antibodies for cancer therapeutics. The Company’s current
focus is DCVax dendritic cell-based cancer vaccine programs.
NWBO’s DCVax platform technology makes use of the
same immune cells as Dendreon’s prostate cancer vaccine Provenge
does. DCVax uses a patient’s own dendritic cells (DCs). The
dendritic cells are extracted from the body, loaded with tumor
antigens, thereby creating a personalized therapeutic vaccine.
Injection of these cells back into the patient initiates a potent
immune response against cancer cells, resulting in delayed time to
progression and prolonged survival.
The Company’s DCVax technology holds competitive
advantages compared to Dendreon’s Provenge and other
competitors which include low cost of manufacturing, ease of
administration, high concentration of activated dendritic cells and
lesser side effects.
NWBO has developed three versions of DCVax products which are
complementary. DCVax-L is developed using the
patient’s own dendritic cells loaded with antigens from the
patient’s own tumor lysate. DCVax-prostate is
developed using the patient’s own dendritic cells loaded with a
recombinant antigen for prostate cancer. The third version of DCVax
is called DCVax-Direct, which is developed using
the patient’s own dendritic cells without any patient tumor tissue.
The DCs are activated, but without addition of tumor antigens. The
cells adhere to the plastic culture surface, which results in
activation. All three versions of DCVax are based on the same DCVax
platform technology. Together, these three versions of DCVax can
cover almost all solid tumor indications. For example, DCVax-L is
used when the patient’s tumor can be surgically removed while
DCVax-Direct can be used when the patient’s tumor cannot be
surgically removed.
The Company’s lead candidate is DCVax-L for the treatment of
Glioblastoma. DCVax-L utilizes NWBO’s dendritic cells (DC) platform
combined with glioblastoma tumor lysate antigens. DCVax-L
demonstrated excellent antitumor activity and safety profile in
Phase I trials.
NWBO is conducting a 240-patient Phase II clinical
trial (designed and powered as a pivotal trial) for DCVax-L, which
could become the second active immunotherapy gaining the FDA
approval. The Phase II trial is also working towards recruiting
patients in Europe. The Company plans to use the European data
together with the US data to seek approval of DCVax-L in the US as
well as in Europe if the trial results are similarly compelling as
in the prior trials.
NWBO’s DCVax-Prostate vaccine was also cleared by the FDA for a
612-patients Phase III trial for non- metastatic
hormone independent prostate cancer patients. The Company is
looking for a partner to initiate the Phase III trial due to the
scale of resources required for such a large trial.
Both DCVax-L and DCVax-Prostate have the potential to become
blockbusters if approved in our view. NWBO has established an
unusually deep pipeline. Its DCVax-Direct technology can target
almost every solid tumor. Current targets include liver, head &
neck, ovarian and pancreatic cancers.
Northwest’s monoclonal antibody CXCR4 is an experimental monoclonal
antibody therapy that targets the functional chemokine receptor,
CXCR4. CXCR4 is highly expressed on many cancer cell types, and is
involved in three functional aspects of cancer cells including cell
division, migration to distant sites, and in setting up metastatic
sites and thus the spread of cancer. These functional aspects make
CXCR4 a particularly attractive target for cancer therapeutics.
Great progress has been made in the past few months in terms of
clinical trials, business development and balance sheet
strengthening. Current valuation is attractive and upside potential
is high at current price level. We are initiating coverage of
Northwest Biotherapeutics (NWBO) with an Outperform rating. Our
12-month price target is $1.50 per share.
Please email scr@zacks.com with NWBO as the subject to
request a free copy of the full research
report.
Follow Zacks Small Cap Research on Twitter at
Twitter.com/ZacksSmallCap
NORTHWEST BIOTH (NWBO): Free Stock Analysis Report
Zacks Investment Research
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024